WebNews
Please enter a web search for web results.
NewsWeb
Certain Series C Preferred Stock of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026.
2+ hour, 34+ min ago (42+ words) marketscreener. com Certain Series C Preferred Stock of Galecto, Inc are subject to a Lock-Up Agreement Ending on 12-APR-2026...
Certain Stock Options of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026.
2+ hour, 34+ min ago (38+ words) marketscreener. com Certain Stock Options of Galecto, Inc are subject to a Lock-Up Agreement Ending on 12-APR-2026...
Number of employees of Eikon Therapeutics, Inc. " NASDAQ: EIKN " Trading View
10+ hour, 3+ min ago (16+ words) Number of employees of Eikon Therapeutics, Inc. " NASDAQ: EIKN'Trading View Number of employees of Eikon Therapeutics, Inc....
Rhythm Biosciences Ltd TEMP Revenue Breakdown " CHIXAU: RHYNA " Trading View
6+ hour, 38+ min ago (17+ words) Rhythm Biosciences Ltd TEMP Revenue Breakdown " CHIXAU: RHYNA'Trading View Rhythm Biosciences Ltd TEMP Top segments and regional performance...
Certain Warrants of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026.
2+ hour, 34+ min ago (40+ words) marketscreener. com Biotechnology & Medical Research Certain Warrants of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026....
Hexem Bio: $10. 4 Million Raised For Blood Stem Cell Rejuvenation Therapy Development
4+ hour, 41+ min ago (262+ words) Hexem Bio, a biotechnology company focused on regenerative medicine, has emerged from stealth with $10. 4 million in seed funding to advance a novel blood stem cell rejuvenation therapy. The round was led by Draper Associates with participation from SOSV, Seraphim, and…...
Eikon Therapeutics, Inc. News " NASDAQ: EIKN " Trading View
5+ hour, 52+ min ago (6+ words) Eikon Therapeutics, Inc. News " NASDAQ: EIKN'Trading View...
FDA Review Looms As Replimune Faces Weak Technical Setup
4+ hour, 40+ min ago (468+ words) Replimune Group shares are down on Thursday. The company faces an upcoming FDA review decision on Friday, 10 April. In October 2025, the U. S. Food and Drug Administration (FDA) accepted the resubmission of the Biologics License Application (BLA) for RP1 in combination with nivolumab…...
PDEU hosts Bioimpact 3. 0 | Ahmedabad News
6+ hour, 47+ min ago (124+ words) PDEU hosts Bioimpact 3. 0 The Times of India Ahmedabad: Pandit Deendayal Energy University (PDEU) in Gandhinagar hosted its flagship biotechnology symposium Bioimpact 3. 0 on Thursday and Friday with participation of industry experts, academicians, professionals and students This year's theme was "Translational Research…...
Health Sector Shifts: Cancer Deals, Supplement Sales, and Drug Approvals | Health
22+ hour, 13+ min ago (255+ words) Health Sector Shifts: Cancer Deals, Supplement Sales, and Drug Approvals'Devdiscourse Health Sector Shifts: Cancer Deals, Supplement Sales, and Drug Approvals C4 Therapeutics, in collaboration with Roche, embarks on a billion-dollar cancer drug venture. Meanwhile, AG1 considers selling the company or a minority…...